ADPT
Adaptive Biotechnologies Corporation
NASDAQ · Healthcare · Biotechnology · US
$24.28
−1.18%Year over year
Reported trailing growth
- Revenue
- +50.1%
- EBITDA
- +83.8%
- EBIT
- +69.1%
- EPS
- +50.3%
- Free cash flow
- +71.0%
- Operating cash flow
- +73.9%
Forward estimates
Based on analyst estimates
- Revenue
- +3.1%
- EBITDA
- -34.8%
- EPS
- +21.9%
Three-year CAGR
- Revenue
- +14.3%
- EBITDA
- +76.8%
- EBIT
- +64.9%
- Net income
- +62.7%
- EPS
- +63.9%
- Free cash flow
- +50.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026